RxDoctor Payments Data

Heather Hoffmann

Nurse Practitioner · Mason, OHNPI 1568098184

Payments from drug & device makers

$1,105in general payments, 2019–2025

Across 45 payments — averaging $24.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$185
  • GSK$184
  • Pharmacyclics LLC, An Abbvie Company$120
  • Johnson & Johnson$111
  • Sanofi$99
  • Genentech USA, Inc.$73
  • plus $333 from 13 others

What the payments were for

  • Food & beverage$1,105100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,105 in reported general payments places this provider in the 85th percentile of 4,700 nurse practitioner providers in Ohio.

See all nurse practitioner providers in Ohio

Medicare billing

Part B allowed, 2024
$60,372
Medicare patients
317
Services billed
547

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter331$280,074
Breztri AerosphereBudesonide/Glycopyr/Formoterol162$130,060
Spiriva RespimatTiotropium Bromide53$34,916
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr27$20,365
Stiolto RespimatTiotropium Br/Olodaterol Hcl31$19,356
SymbicortBudesonide/Formoterol Fumarate47$16,329
Breo ElliptaFluticasone/Vilanterol20$15,094
Advair HfaFluticasone Propion/Salmeterol20$9,308
Albuterol Sulfate HfaAlbuterol Sulfate327$9,301
DuleraMometasone/Formoterol16$7,056
Fluticasone Propionate HfaFluticasone Propionate12$5,889
Arnuity ElliptaFluticasone Furoate11$5,402
Fluticasone-SalmeterolFluticasone Propion/Salmeterol41$3,945
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate30$3,830
Ventolin HfaAlbuterol Sulfate22$2,011

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta$184$320,935389 claims
AstraZenecaBreztri Aerosphere, Symbicort$185$146,389209 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$39$54,27284 claims
MerckDulera$33$7,05616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,700 nurse practitioner providers in Ohio.

Other nurse practitioner in Mason

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →